stockrow
Friday 6 November 2026
Export ZLAB’s income statement to Excel — free account
Zai Lab Limited Unsponsored ADR
ZLAB Healthcare Biotechnology
Zai Lab Limited Unsponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $460.2 million, up 15.3% from fiscal 2024.
- Revenue
- −6.79%
- EPS
- −24.3%
- Free cash flow
- −95.5%
- Total debt
- +24.3%
Quarter to September 2026, against a year earlier
25.34
2.74
+12.12%
Follow ZLAB
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
— | 4 | 4 | 4 |
+8 more TTM periods Free account |
| (29.99%) | (26.91%) | (24.19%) | (22.56%) | ||
| (18.18%) | (16.81%) | (15.70%) | (14.89%) | ||
ROIC |
(21.32%) | (129.34%) | (132.39%) | (109.92%) | |
Return on Tangible Assets |
(40.80%) | (35.39%) | (29.74%) | (26.98%) | |
Average Days of Receivables |
53.95 | 56.50 | 43.54 | 84.17 | |
Free Cash Flow per Share |
0.00 | (1.45) | (1.20) | (1.50) | |
Free Cash Flow |
(196.89) | (162.43) | (132.76) | (164.13) | |
Capital Expenditures |
(37.68) | (29.05) | (31.76) | (13.34) | |
| Other line items | |||||
Cash ROIC |
(24.14%) | (10.39%) | (8.11%) | (9.60%) | |
Accounts Receivable Turnover |
5.86 | 5.69 | 6.94 | 4.81 | |
Accounts Payable Turnover |
0.00 | 1.60 | 1.66 | 1.58 | |
Inventory Turnover |
0.00 | 2.57 | 2.74 | 3.33 | |
Average Days of Payables |
0.00 | 254.93 | 241.40 | 270.50 | |
Days of Inventory on Hand |
0.00 | 169.51 | 164.47 | 142.78 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
54.06% | 52.69% | 49.81% | 48.01% | |
Selling, General and Administrative Expense of Revenue |
63.63% | 62.52% | 61.61% | 60.33% | |
Share Based Compensation of Revenue |
11.85% | 12.96% | 13.97% | 14.26% | |
Interest Coverage |
(45.16) | (44.13) | (42.85) | (44.05) | |
Operating CF/Net income |
0.80 | 0.71 | 0.57 | 0.86 | |
Depreciation/Fixed assets |
0.00 | 0.22 | 0.21 | 0.20 | |
Capex/Depreciation |
0.00 | (2.79) | (3.15) | (1.38) | |
Revenue per Share |
0.00 | 4.03 | 4.09 | 4.20 | |
Operating CF per Share |
0.00 | (1.19) | (0.91) | (1.38) | |
Capex per Share |
0.00 | (0.26) | (0.29) | (0.12) | |
Capex to Sales |
0.09 | 0.06 | 0.07 | 0.03 |
Columns are period end dates · fundamentals updated 5 Nov 2026